ROCKVILLE, Md.--(BUSINESS WIRE)--BIOQUAL, Inc. (OTC Pink: BIOQ) (www.bioqual.com):
| Nine Months Ended | Three Months Ended | ||||||||||||||||
| February 28, | February 29, | February 28, | February 29, | ||||||||||||||
|
2017 |
2016 |
2017 |
2016 |
||||||||||||||
| Revenue | $ | 27,716,798 | $ | 23,398,669 | $ | 9,068,275 | $ | 8,796,046 | |||||||||
| Income Before Income Tax | $ | 4,949,235 | $ | 2,538,783 |
$ |
1,459,486 |
$ |
947,882 | |||||||||
| Net Income | $ | 2,858,135 | $ | 1,466,083 |
$ |
842,786 |
$ |
547,482 | |||||||||
|
Basic Earnings per Share of Common Stock |
$ |
3.20 |
$ |
1.64 |
$ |
.94 |
$ |
.61 |
|||||||||
|
Diluted Earnings per Share of Common Stock |
$ |
3.20 |
$ |
1.64 |
$ |
.94 |
$ |
.61 |
|||||||||
|
Weighted Average Number of Shares Outstanding For Basic Earnings |
893,416 |
893,466 |
893,416 |
893,466 |
|||||||||||||
|
Weighted Average Number of Shares Outstanding For Diluted Earnings |
893,416 |
893,466 |
893,416 |
893,466 |
|||||||||||||
For more detail related to the fiscal year 2017 third quarter results, please visit our web site at www.bioqual.com.
Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts and obtain new contracts; the Company’s ability to obtain new commercial contracts; the performance of the business acquired in the ABL acquisition; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual cost incurred in performing its contracts and the Company’s ability to manage its costs; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.
